Low-dose cytosine arabinoside in acute non-lymphoblastic leukemia

Kumar, Lalit ; Kochupillai, V. ; Dua, Harsch (1989) Low-dose cytosine arabinoside in acute non-lymphoblastic leukemia Cancer, 63 (3). pp. 415-418. ISSN 0008-543X

Full text not available from this repository.

Official URL: http://onlinelibrary.wiley.com/doi/10.1002/1097-01...

Related URL: http://dx.doi.org/10.1002/1097-0142(19890201)63:3<415::AID-CNCR2820630302>3.0.CO;2-D

Abstract

Eighteen previously untreated patients with acute non-lymphoblastic leukemia (ANLL) were treated with cytosine arabinoside (Ara-C) in low does (10 mg/m2 every 12 hours) subcutaneously for 3 weeks. Complete remission (CR) was achieved in four patients (22.and%), 2 myelosuppression was observed in nearly all of them. Thrombocytopenia (20 × 103/ul) was pronounced in the third week of treatment and six patients (33.3%) needed platelet support. Contrary to earlier claims, our experience suggests that treatment with low-dose Ara-C is associated with significant cytopenias. Ara-C does not obviate the need for intensive supportive care and CR rates are no longer better. Low-dose Ara-C does not seem to be a choice in previously untreated ANLL patients who otherwise have a high probability of achieving a CR with standard multidrug chemotherapy protocols.

Item Type:Article
Source:Copyright of this article belongs to John Wiley and Sons.
ID Code:66784
Deposited On:27 Oct 2011 06:38
Last Modified:27 Oct 2011 06:38

Repository Staff Only: item control page